 "RPG Life Sciences gains on getting EUGMP certification for formulation facility at Ankleshwar")
RPG Life Sciences has rallied 11% to Rs 260 on the BSE in early morning trade after the pharmaceutical company announced that it has received GMP Certificate from Bavarian Authority, a competent authority in Germany.
“The company has received GMP Certificate from Bavarian Authority, a competent authority in Germany, as per EUGMP standards for its formulation manufacturing facility at 3102/A, G.l.D.C. Industrial Estate, Ankleshwar, District Bharuch, Gujarat,” RPG Life Sciences said in a press release.
Bavarian Authority had conducted audit of the manufacturing facility in early March 2016.
“This is a major milestone for us. The certification will help in boosting sales by expanding the company's geographical presence in the European markets. It also reinforces the quality systems established by the company in line with the current stringent good manufacturing practices,” commented CT. Renganathan, Managing Director, RPG Life Sciences.
At 09:23 AM, the stock was up 6% at Rs 248 on the BSE. A combined 115,764 shares changed hands on the counter on the BSE and NSE so far.
“The company has received GMP Certificate from Bavarian Authority, a competent authority in Germany, as per EUGMP standards for its formulation manufacturing facility at 3102/A, G.l.D.C. Industrial Estate, Ankleshwar, District Bharuch, Gujarat,” RPG Life Sciences said in a press release.
Bavarian Authority had conducted audit of the manufacturing facility in early March 2016.
“This is a major milestone for us. The certification will help in boosting sales by expanding the company's geographical presence in the European markets. It also reinforces the quality systems established by the company in line with the current stringent good manufacturing practices,” commented CT. Renganathan, Managing Director, RPG Life Sciences.
At 09:23 AM, the stock was up 6% at Rs 248 on the BSE. A combined 115,764 shares changed hands on the counter on the BSE and NSE so far.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%